LUMOSA THERAPEUTICS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 182 TWD | 0.00% |
|
-0.82% | +166.47% |
| May. 14 | Lumosa Therapeutics Co., Ltd. Announces the Change of Chairperson | CI |
| May. 14 | Lumosa Therapeutics Co., Ltd. Announces the Change in Juristic-Person Director Representative | CI |
| Sales 2024 * | 59M 1.83M | Sales 2025 * | 816M 25.3M | Capitalization | 30.03B 931M |
|---|---|---|---|---|---|
| Net income 2024 * | -444M -13.77M | Net income 2025 * | 786M 24.37M | EV / Sales 2024 * | 505 x |
| Net cash position 2024 * | 259M 8.03M | Net cash position 2025 * | 954M 29.58M | EV / Sales 2025 * | 35.6 x |
| P/E ratio 2024 * |
-67.7
x | P/E ratio 2025 * |
38.2
x | Employees | 47 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.33% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -0.82% | ||
| Current month | +5.81% | ||
| 1 month | +8.33% | ||
| 3 months | +36.33% | ||
| 6 months | +189.81% | ||
| Current year | +166.47% |
1 week
179.00
185.00
1 month
168.50200.00
Current year
68.00233.50
1 year
53.90233.50
3 years
30.50233.50
5 years
21.00233.50
10 years
21.00233.50
| Managers | Title | Age | Since |
|---|---|---|---|
Jung Chin Lin
CEO | Chief Executive Officer | 70 | 11-09-15 |
Chia Chi Yang
DFI | Director of Finance/CFO | - | 22-01-31 |
June Kuo
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wan Lai Cheng
BRD | Director/Board Member | - | 14-07-24 |
Jung Chin Lin
CEO | Chief Executive Officer | 70 | 11-09-15 |
I Hsiung Chang
BRD | Director/Board Member | - | 16-01-25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 182 | 0.00% | 291,082 |
| 24-05-22 | 182 | -1.09% | 226,738 |
| 24-05-21 | 184 | +1.38% | 180,548 |
| 24-05-20 | 181.5 | -1.89% | 347,521 |
| 24-05-17 | 185 | +0.82% | 619,668 |
End-of-day quote Taipei Exchange, May 22, 2024
More quotes
LUMOSA THERAPEUTICS CO., LTD. is a Taiwan-based company principally engaged in the development of new drugs. The Company is engaged in the development of new drugs for unmet medical needs in the fields of central nervous system (CNS), oncology, and inflammatory diseases. The Company is engaged in scientific licensing and new drug development under the reSEARCH and DEVELOPMENT model.
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
182
TWD
Average target price
233.3
TWD
Spread / Average Target
+28.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +166.47% | 930M | |
| +10.79% | 115B | |
| +11.65% | 106B | |
| -6.20% | 24.69B | |
| -2.33% | 21.97B | |
| -6.03% | 19.27B | |
| -13.41% | 17.56B | |
| -40.50% | 17.32B | |
| +6.64% | 14.03B | |
| +31.84% | 12.13B |
- Stock Market
- Equities
- 6535 Stock
